Education
About Us
Working with TipRanks
Follow Us
Renovorx, Inc. (RNXT)
:RNXT
RNXT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.75 - $1.69
Previous CloseN/A
Volume39.72K
Average Volume (3M)172.60K
Market Cap
$35.02M
Enterprise Value$36.04M
Total Cash (Recent Filing)$14.58M
Total Debt (Recent Filing)$283.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 17, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,645,885
10 Day Avg. Volume295,957
30 Day Avg. Volume172,599
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue150.18
Enterprise Value/Gross Profit246.88
Enterprise Value/Ebitda-3.11
Forecast
1Y Price Target
$6.00Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical ResultsPositive data from the first interim analysis demonstrated an overall survival of approximately 21.5 months, compared to 15.5 months in the control arm, with a favorable safety profile.
Clinical TrialsJohns Hopkins commenced patient enrollment in the ongoing P3 TIGeR-PaC trial, strengthening the clinical sites participating in the trial across the US.
Bears Say
EarningsThe company reported a net loss of $0.40 per diluted share for the fourth quarter.
Financial PerformanceFor 1Q25, the company reported $197,000 in revenue and a net loss of $0.08 per diluted share, compared to an estimate of $335,000 and a net loss of $0.07 per diluted share.
RenovoRx News
RNXT FAQ
What was Renovorx, Inc.’s price range in the past 12 months?
Renovorx, Inc. lowest stock price was $0.75 and its highest was $1.69 in the past 12 months.
What is Renovorx, Inc.’s market cap?
Renovorx, Inc.’s market cap is $35.02M.
When is Renovorx, Inc.’s upcoming earnings report date?
Renovorx, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 92 days.
How were Renovorx, Inc.’s earnings last quarter?
Renovorx, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.005.
Is Renovorx, Inc. overvalued?
According to Wall Street analysts Renovorx, Inc.’s price is currently Undervalued.
Does Renovorx, Inc. pay dividends?
Renovorx, Inc. does not currently pay dividends.
What is Renovorx, Inc.’s EPS estimate?
Renovorx, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Renovorx, Inc. have?
Renovorx, Inc. has 36,645,885 shares outstanding.
What happened to Renovorx, Inc.’s price movement after its last earnings report?
Renovorx, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went down -22.581%.
Which hedge fund is a major shareholder of Renovorx, Inc.?
Currently, no hedge funds are holding shares in RNXT
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (525.00% Upside)
$6.00 (525.00% Upside)
Blogger Sentiment
Bullish
RNXT Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $29.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 20.9%
Last 30 Days ▼ 20.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.96%
12-Months-Change
Fundamentals
Return on Equity
-107.11%
Trailing 12-Months
Asset Growth
13.65%
Trailing 12-Months
Company Description
Renovorx, Inc.
RenovoRx (RNXT) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company is dedicated to improving patient outcomes by delivering chemotherapy directly to tumors via its proprietary RenovoTAMP (Trans-Arterial Micro-Perfusion) therapy platform. This platform is designed to enhance the efficacy of existing chemotherapeutic agents while minimizing systemic exposure and associated side effects.
RNXT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong clinical trial results, better-than-expected first-quarter revenue, and robust demand for RenovoCath. However, there were some increases in operating expenses and limited international market presence.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$6.00
▲(525.00% Upside)
Technical Analysis
Tempest Therapeutics
―
Rein Therapeutics
―
ALX Oncology Holdings
―
Surrozen
―
MiNK Therapeutics
―
Ownership Overview
3.32% Insiders
4.41% Mutual Funds
0.04% Other Institutional Investors
88.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---